The viability of PANC-1 pancreatic cancer cells is negatively impacted by sulforaphane and BITC. (A) PANC-1 cells were treated with 5, 10, and 20 μM of sulforaphane for 3 and 5 days, after which MTT assays were used to assess cell viability. (B) Treatment of PANC-1 with 2.5 20 μM sulforaphane results in a marked increase in cleaved PARP, but otherwise has little to no impact on levels of phospho-ERK1/2 and pSTAT3. (C) Treatment of PANC-1 with 5, 10 and 20 μM BITC lowers PANC-1 viability to a lesser extent than that exhibited by sulforaphane. (D) BITC reduces levels of pSTAT3 in a dose-dependent fashion and increases levels of PARP cleavage, but has minimal effect on levels of phospho-ERK1/2.